[1] Bedford M T and Clarke SG (2009) Protein Arginine Methylation in Mammals: Who, What, and Why, Mol. Cell 33, 1-13.
[2] Wei H, Mundade R, Lange KC, et al. (2014) Protein arginine methylation of non-histone proteins and its role in diseases, Cell Cycle 13, 32-41.
[3] KaniskanH Ü, Konze KD, and Jin J. (2015) Selective Inhibitors of Protein Methyltransferases, J. Med. Chem. 58, 1596-1629.
[4] Yang YZ and Bedford MT (2013) Protein arginine methyltransferases and cancer, Nat. Rev. Cancer 13, 37-50.
[5] Yoshimatsu M, Toyokawa G, Hayami S, et al. (2011) Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers, Int. J. Cancer 128, 562-573.
[6] Kaniskan HÜ, Szewczyk MM, Yu Z, et al. (2015) A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl 54, 5166-70.
[7] Mitchell LH, Drew AE, Ribich SA, et al. (2015) Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett. 6, 655-9.
[8] Eram MS, Shen Y, Szewczyk M, et al. (2015) A Potent, Selective and Cell-active Inhibitor of Human Type I Protein Arginine Methyltransferases, ACS Chemical Biology DOI: 10.1021/acschembio.5b00839.